FIELD: chemistry.
SUBSTANCE: invention pertains to biotechnology. Described is an anti-HIV monoclonal antibody or its functional fragment which has in the variable region of the H-(heavy) chain regions which determine complementarity, CDR1, CDR2 and CDR3, which have sequences given in the description, and CDR1, CDR2 and CDR3 regions with sequences given in the description in the variable region of the L-(light) chain. Expression vectors which code fragments of the heavy and light chain of the described antibody and host cells which are transformed by the said vectors are disclosed. A method for detecting the HIV strain and a method for individual passive immunotherapy are disclosed.
EFFECT: invention enables to obtain an antibody which enables neutralisation of HIV infection without an autoimmune side effect.
17 cl, 9 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY OR FRAGMENT THEREOF WITH HIV-NEUTRALISING ACTIVITY | 2005 |
|
RU2380378C2 |
| COMPOSITION FOR PREVENTING AND/OR TREATING INFECTION, CAUSED BY HIV-1 | 2012 |
|
RU2603262C2 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | 2014 |
|
RU2693438C2 |
| ANTIBODY FOR BLyS | 2013 |
|
RU2613422C2 |
